INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo NOVA T 380

SCHEDULING STATUS:
S4

PROPRIETARY NAME
(and dosage form):

NOVA T 380

Intrauterine device (IUD)

COMPOSITION
Nova T 380 is an
intrauterine device made of polyethylene and wound with copper wire with a silver core. The surface area of the copper is 380 mm². The polyethylene body, shaped as a modified T is impregnated with barium sulphate. Removal threads, pigmented with iron oxide are attached to the base of the vertical arm of the T.

PHARMACOLOGICAL CLASSIFICATION
A. 34 Other –intrauterine device

PHARMACOLOGICAL ACTION
Copper IUDs prevent pregnancy by preventing fertilisation. This is based on the inhibition of sperm and egg transport and/or the capacity of the sperm to fertilise eggs. This happens through cytotoxic and phagocytic effects before the egg reaches the uterine cavity. After the removal of Nova T 380 fertility is promptly restored.
The pregnancy rate with Nova T 380 has been 0,6 per 100 woman-years.

INDICATIONS
Contraception.

CONTRA-INDICATIONS
Known or suspected pregnancy; current or recurrent pelvic inflammatory disease, lower genital tract infection; postpartum endometritis, infected abortion during the past three months; untreated cervicitis; untreated cervical dysplasia; untreated uterine or cervical malignancy; undiagnosed abnormal uterine bleeding; congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity; copper allergy; Wilson’s disease; coagulation disturbances; conditions associated with increased susceptibility to infections.

WARNINGS
Nova T 380 may increase menstrual blood loss and dysmenorrhoea. Nova T 380 may not be the method of first choice for women with excessive menstrual bleeding, anaemia, dysmenorrhoea, or for women receiving anticoagulants. If these conditions develop during the use of Nova T 380, removal of the device should be considered.
Nova T 380 may be used with caution in women who have congenital heart disease or valvular heart disease at risk of infective endocarditis. Antibiotic prophylaxis should be administered to these patients when inserting or removing the intrauterine device.
Nova T 380 is not the method of first choice for young nulligravid women. In this group, the pregnancy rates and removal rates for expulsion, bleeding and/or pain, and for infection have been reported higher than in other users.

DOSAGE AND DIRECTIONS FOR USE
Nova T 380 is supplied sterile, sterilised by irradiation. It is for single use only. Do not use if the pouch is damaged or open. Do not resterilise. Use before the date shown on the pouch label. To be inserted by a qualified health care professional.
Nova T 380 is inserted into the uterine cavity. It is effective for five years.
Insertion and removal/replacement
Before insertion, the woman must be informed on the efficacy, risks and side effects of Nova T 380. A physical examination including pelvic examination and a cervical smear should be performed. Pregnancy, genital infection and sexually transmitted diseases should be excluded. The position of the uterus and the size of the uterine cavity should be determined. The instructions for insertion should be followed carefully. The woman should be re-examined 4 to 12 weeks after insertion and once a year thereafter, or more frequently if clinically indicated.
Insertion is recommended during or shortly following menstruation. If pregnancy is excluded, Nova T 380 may be inserted at any time of the cycle. The small diameter of the insertion tube, which is easy to introduce, makes dilatation usually unnecessary. It can be replaced by a new device at any time in the cycle. Nova T 380 can also be inserted immediately after first trimester abortion. Postpartum insertions should be postponed until six weeks after delivery as they are associated with high rates of perforation and expulsion.
Nova T 380 is removed by gently pulling on the threads with forceps. If the threads are not visible and the device is in the uterine cavity, removal should be postponed until after the next menstrual bleeding since the threads usually become visible immediately after menstruation. If they are still not visible, the device may be removed using a narrow tenaculum. This may require dilatation of the cervical canal.
Nova T 380 should be removed after five years. If the woman wishes to continue using the method, a new device can be inserted at the same time.
If pregnancy is not desired, the removal should be carried out during menstruation. If the device is removed mid-cycle and the woman has had intercourse within a week, she is at risk of pregnancy unless a new device is inserted immediately following removal.
Insertion and removal may be associated with some pain and bleeding. The procedure may precipitate fainting as a vasovagal reaction, and a seizure in an epileptic patient.
Instructions for use
NOVA T 380 IS SUPPLIED STERILE, STERILISED BY IRRADIATION. IT IS FOR SINGLE USE ONLY. DO NOT RESTERILISE. Do not use if the pouch is damaged or open. Insert the device before the expiry date shown on the pouch label. Each device should be handled with aseptic precautions. Special instructions for insertion are in the package. After removal, Nova T 380 should be disposed of in accordance with the local guidelines for the handling of biohazardous waste.

SIDE EFFECTS AND SPECIAL PRECAUTIONS
Side effects
Increased menstrual bleeding; spotting; dysmenorrhoea; lower abdominal or back pain; anaemia. Pregnancy in the case of the method failure may be ectopic. Pelvic inflammatory disease may occur during the use of Nova T 380. The Nova T 380 or parts of it may perforate or penetrate the uterine wall. Allergic skin reactions may occur.
Special precautions
Pelvic infection: The insertion tube protects Nova T 380 from contamination with micro-organisms during the insertion. In users of copper IUDs, the highest rate of pelvic infections occurs during the first month after insertion and decreases later. Known risk factors for pelvic inflammatory disease are multiple sexual partners, frequent intercourse and young age. Pelvic infection may impair fertility and increase the risk of ectopic pregnancy.
If the woman experiences recurrent endometritis or pelvic infections, or if acute infection does not respond to treatment within a few days, the Nova T 380 must be removed.
Bacteriological examinations are indicated and monitoring is recommended, even with discrete symptoms indicative of infection, such as pathologic discharge.
Expulsion: Symptoms of the partial or complete expulsion of any IUD may include bleeding or pain. However, a device can be expelled from the uterine cavity without the woman noticing it. Partial expulsion may decrease the effectiveness of Nova T 380. A displaced device should be removed and a new device inserted.
The woman should be advised how to check the threads of the IUD.
Perforation: Perforation or penetration of the uterus or cervix by the IUD may occur, most often during insertion. The risk is increased during the postpartum period. Such a device must be removed as soon as possible.
Ectopic pregnancy: Even though ectopic pregnancies may occur when IUDs are used, current data indicate that copper IUD users do not have a higher overall risk of ectopic pregnancy than women using no contraception. However, a pregnancy with an IUD in place is more likely to be ectopic than if pregnancy occurs without an IUD in situ. Women with a previous ectopic pregnancy, pelvic surgery or pelvic infection carry a higher risk of ectopic pregnancy. The possibility of ectopic pregnancy should be considered in the case of lower abdominal pain - especially in connection with missed periods or if an amenorrhoeic woman starts bleeding.
Lost threads: If the retrieval threads are not visible at the cervix on follow-up examinations, pregnancy must be excluded. The threads may have been drawn up into the uterus or cervical canal and may reappear during the next menstrual period. If pregnancy has been excluded, the threads may usually be located by gently probing with a suitable instrument. If they cannot be found, the device may have been expelled. Ultrasound diagnosis may be used to ascertain the position of the IUD. If ultrasound is not available or unsuccessful, X-ray may be used to locate Nova T 380.
Use in pregnancy and lactation
Nova T 380 is not to be used during an existing or suspected pregnancy.
If the woman becomes pregnant when using Nova T 380 removal of the device is recommended, since the IUD left in situ may increase the risk of abortion and preterm labour. Removal of the IUD or probing of the uterus may result in spontaneous abortion. If the device cannot be gently removed, termination of the pregnancy may be considered. If the woman wishes to continue the pregnancy and the device cannot be withdrawn, she should be informed about these risks and the possible consequence of premature birth to the infant. In addition, ectopic pregnancy should be excluded and the course of such a pregnancy should be closely monitored. The woman should be instructed to report all symptoms that suggest complications of the pregnancy, like cramping abdominal pain with fever. She should be informed that, to date, there is no evidence of birth defects in cases where a pregnancy continues to term with the IUD in place.
Lactation
Nova T 380 does not interfere with lactation.

IDENTIFICATION
A white plastic body - shaped as a modified T, with silver-cored copper wire wound around the vertical arm and removal threads tied to the loop of the vertical arm.

PRESENTATION
The device with accessories is packed in a heat-sealed sterilisation pouch of polyester/ polyethylene/polyamide.

STORAGE INSTRUCTIONS
Store below 30°C. Protect from direct sunlight and moisture. Keep out of reach of children.

REGISTRATION NUMBER
34/34/0132

NAME AND BUSINESS ADDRESS OF THE APPLICANT
Schering (Pty) Ltd
(Reg No: 1964/009072/07)
106 Sixteenth Road
Randjespark
Midrand        1685
P O Box 5278
Halfway House        1685

DATE OF PUBLICATION OF THIS PACKAGE INSERT
12 February 2002

SCHERING (PTY) LTD
(Reg No: 1964/009072/07)
Subsidiary of
Schering AG        Germany

Updated on this site: April 2003
Current: January 2005
Source: Pharmaceutical Industry

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2005